| Revision as of 22:50, 21 February 2010 editحسن علي البط (talk | contribs)Extended confirmed users, Pending changes reviewers19,940 editsm Quick-adding category Nitro compounds (using HotCat)← Previous edit | Revision as of 06:10, 18 October 2010 edit undoNirmos (talk | contribs)Extended confirmed users3,574 editsm Replaced Category:Nitro compounds with the more specific Category:Nitrobenzenes.Next edit → | ||
| Line 36: | Line 36: | ||
| ] | ] | ||
| ] | ] | ||
| ] | ] | ||
Revision as of 06:10, 18 October 2010
Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H12N2O4S |
| Molar mass | 244.267 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype. It has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.
References
- Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA. Discovery of BRL 50481 , a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Molecular Pharmacology. 2004 Dec;66(6):1679-89. PMID 15371556
- Pekkinen M, Ahlström ME, Riehle U, Huttunen MM, Lamberg-Allardt CJ. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Bone. 2008 Jul;43(1):84-91. PMID 18420479